Browse Health
Urologist
13 years of experience
Video profile
Accepting new patients

Education ?

Medical School Score Rankings
University of North Carolina (1997)
  • Currently 4 of 4 apples
Top 25%

Awards & Distinctions ?

Associations
American Board of Urology
American Urological Association

Affiliations ?

Dr. Nelson Vick is affiliated with 17 hospitals.

Hospital Affilations

Score

Rankings

  • Northeast Medical Center
    Urology
    920 Church St N, Concord, NC 28025
    • Currently 4 of 4 crosses
    Top 25%
  • Mercy Hospital
    2001 Vail Ave, Charlotte, NC 28207
    • Currently 4 of 4 crosses
    Top 25%
  • Presbyterian Hospital
    Urology
    200 Hawthorne Ln, Charlotte, NC 28204
    • Currently 4 of 4 crosses
    Top 25%
  • Presb Orthopaedic Hospital
    1901 Randolph Rd, Charlotte, NC 28207
    • Currently 4 of 4 crosses
    Top 25%
  • Carolinas Medical Center
    8800 N Tryon St, Charlotte, NC 28262
    • Currently 4 of 4 crosses
    Top 25%
  • University Hospital - Charlotte
    Urology
    8800 N Tryon St, Charlotte, NC 28262
    • Currently 3 of 4 crosses
    Top 50%
  • Presbyterian Hospital Matthew
    1500 Matthews Township Pkwy, Matthews, NC 28105
    • Currently 2 of 4 crosses
  • Presbyterian-Huntersville
    10030 Gilead Rd, Huntersville, NC 28078
    • Currently 1 of 4 crosses
  • Carolinas Medical Center MercyMain
  • Presbyterian HospitalPresbyterian Orthopaedic Hospital
  • Presbyterian Matthews
  • Presbyterian SameDay Surgery Huntersville
  • PH Charlotte/Ortho
  • Presbyterian Hospital Charlotte
  • CMC University
  • Presbyterian Hospital Huntersville
  • Carolina Medical Center - Pineville
    10628 Park Rd, Charlotte, NC 28210
  • Publications & Research

    Dr. Nelson Vick has contributed to 4 publications.
    Title The Efficacy, Safety and Tolerability of Intracavernous Pnu-83757 for the Treatment of Erectile Dysfunction.
    Date June 2002
    Journal The Journal of Urology
    Excerpt

    PURPOSE: Despite the introduction of sildenafil citrate many men with erectile dysfunction remain dependent on intracavernous therapy. While the majority achieves satisfactory results with currently available intracavernous preparations, all preparations have undesirable side effects, including priapism, fibrosis and post-injection pain. We determined the efficacy, safety and tolerability of the erectogenic potassium channel opener PNU-83757. MATERIALS AND METHODS: We selected 66 men with erectile dysfunction of vascular etiology for intracavernous injection of PNU-83757 in a single dose, single blind, placebo controlled study. Of the 6 patients allocated into each of 11 dose groups 5 received active drug and 1 received placebo. Groups received progressive doses of PNU-83757 or placebo. Holter monitoring was performed at scheduled intervals. Heart rate, and systolic, diastolic and mean blood pressure were assessed at scheduled intervals. Blood samples were obtained for pharmacokinetic study. Patients were evaluated at regular intervals for adverse events. Investigators and patients evaluated efficacy. RESULTS: The first complete erection was observed at 10 mcg. Of the 25 patients receiving active drug in the 60 to 140 mcg. groups only 1 had no erectile response, 15 had partial erection and 9 had complete erection. No serious adverse events or cardiovascular effects were noted. CONCLUSIONS: The minimum effective dose for complete erection was 10 mcg. The erectile response reached a plateau between 60 and 140 mcg., suggesting minimal improvement in efficacy at higher doses. Patient evaluation of erectile quality corresponded well with that of investigators. PNU-83757 was efficacious and extremely well tolerated, and the only adverse events were mild. No cardiovascular side effects were observed at any dose. PNU-83757 intracavernous injections caused no post-injection pain in any patient, which may make PNU-83757 superior to alprostadil in a select group. Further study is required to evaluate the efficacy of PNU-83757 combined with other drugs and with sexual stimulation.

    Title Urethral Atresia in a Neonate with Alveolar Capillary Dysplasia and Pulmonary Venous Misalignment.
    Date May 2000
    Journal Urology
    Excerpt

    Urethral atresia and alveolar capillary dysplasia (ACD) are rare congenital malformations. Urethral atresia is associated with severe pulmonary hypoplasia secondary to oligohydramnios. ACD is associated with pulmonary venous misalignment, results in severe pulmonary hypertension, and is uniformly fatal. We present a case of urethral atresia with successful, early placement of vesicoamniotic shunting, with resolution of the oligohydramnios, in which the neonate rapidly progressed to respiratory failure and death. Postmortem examination confirmed urethral atresia and diagnosed ACD. Given the surprisingly high mortality rate after vesicoamniotic shunting in patients with urethral atresia, we question whether there might be a possible link to ACD.

    Title Inefficient Gene Transfer by Adenovirus Vector to Cystic Fibrosis Airway Epithelia of Mice and Humans.
    Date November 1994
    Journal Nature
    Excerpt

    The success of adenoviral vectors for gene therapy of lung disease in cystic fibrosis (CF) depends on efficient transfer of the complementary DNA encoding the correct version of the cystic fibrosis transmembrane regulator (CFTR) to the affected columnar epithelial cells lining the airways of the lung. Pre-clinical studies in vitro suggest that low doses of adenovirus vectors carrying this CFTR cDNA can correct defective Cl- transport in cultured human CF airway epithelia. Here we use mice carrying the disrupted CF gene to test the efficacy of this transfer system in vivo. We find that even repeated high doses can only partially (50%) correct the CF defect in Cl- transport in vivo and do not correct the Na+ transport defect at all. We investigated this discrepancy between the in vivo and in vitro transfer efficiency using CF mouse and human samples, and found that it reflects a difference in the susceptibility to adenovirus-5 transduction of the epithelial cell types dosed in vivo (columnar) and in vitro (basal-cell-like). These studies indicate that more efficient adenoviral gene-transfer vectors and/or refinement of dosing strategies are needed for therapy of CF lung disease.

    Title Hyperabsorption of Na+ and Raised Ca(2+)-mediated Cl- Secretion in Nasal Epithelia of Cf Mice.
    Date July 1994
    Journal The American Journal of Physiology
    Excerpt

    We investigated the effect of homozygous genetic disruption of the murine cystic fibrosis transmembrane regulator (CFTR) gene on regulation of the rates of Na+ absorption and Cl- secretion by nasal epithelia in cystic fibrosis (CF) mice. The basal in vivo nasal potential difference (PD; -28.8 +/- 1.8 mV, n = 10) and amiloride-sensitive PD (delta 13.8 +/- 1.0 mV, n = 10) were raised in CF mice compared with controls [-7.8 +/- 0.8 mV, n = 14 (basal); delta 4.5 +/- 0.7 mV, n = 14 (amiloride)], consistent with raised Na+ transport. In vitro studies of freshly excised nasal epithelia confirmed that CF epithelia exhibited a greater basal equivalent short-circuit current (Ieq; 63.5 +/- 12 microA/cm2, n = 15) vs. control (30.2 +/- 7.2 microA/cm2, n = 16) and amiloride-sensitive Ieq (delta 46.2 +/- 12.5 microA/cm2) vs. control (delta 11.3 +/- 4.5 microA/cm2). Tissue from normal mice failed to secrete Cl- in response to ionomycin (delta Ieq: -1.2 +/- 1.9 microA/cm2, n = 18), whereas CF murine tissue responded with a large rise in Ieq (delta 55.1 +/- 19.1 microA/cm2, n = 13). We conclude that CF murine nasal epithelia exhibit Na+ hyperabsorption, providing strong evidence for a regulatory link between CFTR and Na+ channel activity in airway epithelia. We speculate that upregulation of the Ca(2+)-mediated Cl- secretory pathway buffers the severity of airway disease in the CF mouse.

    Similar doctors nearby

    Dr. Daniel Watson

    Urology
    20 years experience
    Charlotte, NC

    Dr. Lisette Bennett

    Urology
    7 years experience
    Charlotte, NC

    Dr. Sharon Hinson

    Urology
    20 years experience
    Charlotte, NC

    Dr. Theodore Stamatakos

    Urology
    22 years experience
    Harrisburg, NC

    Dr. Charles Jennings

    Urology
    30 years experience
    Charlotte, NC

    Dr. Luis Perez

    Urology
    22 years experience
    Charlotte, NC
    Search All Similar Doctors